RE:RE:COVID AND THE HEARTColchicine was the anti-inflammatory drug recently FDA approved for heart disease and inflammation. It set a new precedent for inflammation and heart disease. The trial investigator in charge of CZO's avenanthramide clinical trial worked on the FDA approved drug. He also worked on colchicine for COVID. Colchcine doesn't have an ideal safety profile and avenanthramide may be able to beat it given its profile. CZO will find the maximum tolerated dose perhaps in the next 9 months if prior stated timelines fo safety results hold. The patients in CZO's clinical trial will have a three day hospital stay.
Wikepedia:
Adverse effects[edit]
Deaths – both accidental and intentional – have resulted from overdose of colchicine.[19] Typical side effects of moderate doses may include gastrointestinal upset, diarrhea, and neutropenia.[14] High doses can also damage bone marrow, lead to anemia, and cause hair loss. All of these side effects can result from inhibition of mitosis,[30] which may include neuromuscular toxicity and rhabdomyolysis.[19]